AI Drug Discovery
Insilico and SK Biopharmaceuticals Launch $2.5 Billion AI Drug Discovery Venture Targeting CNS Diseases
Key Points
SK Biopharmaceuticals CEO Donghoon Lee said the collaboration is not just a single program: “we see this collaboration as a scalable and repeatable growth platform that can be leveraged for future target discovery and development opportunities.”
Insilico co-CO and chief business officer Alex Zhavoronkov said the two companies intend to “unlock breakthrough therapies, spanning both traditional small molecules and advanced new modalities, to address critical patient needs.”
SK said using Insilico’s Pharma.AI during initial discovery and preclinical phases is expected to reduce the time to identify drug candidates by nearly 50% versus traditional research methods, while also significantly lowering early discovery costs.
Insilico said its AI platform has produced tangible output already: it has nominated 31 preclinical candidates since 2021, including 13 programs that have received IND approvals or clearance.
Beyond the SK partnership, TipRanks reported that Insilico is expanding its AI stack with MMAI Gym, described as a benchmarking and training environment for scientific AI that has attracted external partners—supporting its goal of a repeatable “target-to-candidate” model.
InSilico Medicine and SK Biopharmaceuticals have signed an AI drug discovery deal worth potentially more than $2.5 billion, targeting neuroimmune disorders of the central nervous system. The agreement, signed June 18 at the BIO 2026 Convention, includes $18 million in upfront and near-term payments, plus milestones and single-digit royalties on future sales, according to TipRanks.
InSilico will use its Pharma.AI platform to find and refine drug candidates through preclinical stages. SK Biopharmaceuticals will then take the lead on late-stage development and commercialization, using its CNS expertise and U.S. commercial infrastructure, Fierce Biotech reported.
SK Bets AI Can Halve Early Drug Discovery Time
SK Biopharmaceuticals says using InSilico's Pharma.AI platform could cut the time to identify drug candidates by nearly 50% versus traditional research methods. It also expects to significantly lower early discovery costs. The focus areas are neuroinflammatory, neurodegenerative, and rare neurological diseases — a field historically plagued by high failure rates and slow timelines.
SK CEO Donghoon Lee framed the deal as more than a one-time experiment. "We see this collaboration as a scalable and repeatable growth platform that can be leveraged for future target discovery and development opportunities," he said. Lee has been pushing SK to expand beyond cenobamate (Xcopri), its epilepsy drug, into broader CNS areas. This deal is the first AI-based project under SK's newly formed Open Innovation Center.
InSilico's AI Platform Already Has a Track Record
InSilico is not starting from scratch. Since 2021, its AI platform has nominated 31 preclinical drug candidates. Of those, 13 programs have received IND approvals or clearance — meaning regulators allowed them to begin human trials. That track record helped convince SK to commit to a multi-billion dollar framework rather than a single program.
InSilico co-CEO and chief business officer Alex Zhavoronkov said the goal is broad. "The intent is to unlock breakthrough therapies, spanning both traditional small molecules and advanced new modalities, to address critical patient needs," he said. "New modalities" could include RNA-based therapies or complex biologics, moving beyond standard pills. TipRanks also reported that InSilico is building out MMAI Gym, a tool that lets external partners audit and benchmark its AI models — a key step toward building trust with partners like SK.
A $2.5B Headline With Most of the Money Still Years Away
Analysts are quick to note that the $2.5 billion figure is heavily back-loaded. The confirmed upfront and near-term payments total just $18 million. The rest is tied to development and commercialization milestones that may take years to hit — if they are reached at all. Fierce Biotech described it as "heavily backloaded," a structure common in AI drug discovery deals.
For SK, that structure is actually a feature. The company gains access to a cutting-edge AI platform for a manageable upfront cost. If the AI candidates fail, the financial damage is limited. If they succeed, the neuroimmune drug market more than justifies the total payout. SK controls the process through a stage-gate system, reviewing InSilico's AI outputs before committing to next steps.
Skeptics Warn AI Still Cannot Fix CNS's Biggest Problem
Not everyone is convinced. Some researchers argue that finding a drug candidate faster does not solve the core problem in CNS drug development: most drugs fail in Phase II trials because the biological target turns out not to be the real cause of the disease. This has been the central failure in Alzheimer's research for two decades.
The concern is that AI can optimize a molecule to fit a target perfectly, but if the target itself is wrong, the drug still fails in humans. Critics are watching InSilico's MMAI Gym closely, looking for evidence that the AI understands disease causality — not just molecular patterns. The stage-gate process SK insisted on is widely seen as a necessary check on that risk, according to TipRanks.
Sentiment
Mostly PositivePublishers
13
Articles
5
Reach
18
